[go: up one dir, main page]

WO2008129239A3 - Traitement pour le cancer - Google Patents

Traitement pour le cancer Download PDF

Info

Publication number
WO2008129239A3
WO2008129239A3 PCT/GB2008/001303 GB2008001303W WO2008129239A3 WO 2008129239 A3 WO2008129239 A3 WO 2008129239A3 GB 2008001303 W GB2008001303 W GB 2008001303W WO 2008129239 A3 WO2008129239 A3 WO 2008129239A3
Authority
WO
WIPO (PCT)
Prior art keywords
homologous recombination
treatment
cancer
agents
inhibit homologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/001303
Other languages
English (en)
Other versions
WO2008129239A2 (fr
Inventor
Thomas Helleday
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of WO2008129239A2 publication Critical patent/WO2008129239A2/fr
Publication of WO2008129239A3 publication Critical patent/WO2008129239A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation d'un agent qui inhibe la recombinaison homologue dans le traitement du cancer ou de maladies à phénotype présentant une hyper-recombinaison homologue. L'invention concerne également un procédé de traitement de cellules chez un mammifère, y compris un humain, ayant un phénotype à hyper-recombinaison homologue, ledit procédé comprenant d'administrer au mammifère une quantité efficace sur le plan thérapeutique d'un agent qui inhibe la recombinaison homologue.
PCT/GB2008/001303 2007-04-19 2008-04-15 Traitement pour le cancer Ceased WO2008129239A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0707556.7 2007-04-19
GB0707556A GB0707556D0 (en) 2007-04-19 2007-04-19 Treatment for cancer

Publications (2)

Publication Number Publication Date
WO2008129239A2 WO2008129239A2 (fr) 2008-10-30
WO2008129239A3 true WO2008129239A3 (fr) 2009-03-12

Family

ID=38135060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/001303 Ceased WO2008129239A2 (fr) 2007-04-19 2008-04-15 Traitement pour le cancer

Country Status (2)

Country Link
GB (1) GB0707556D0 (fr)
WO (1) WO2008129239A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10724100B2 (en) 2015-09-16 2020-07-28 Institute For Cancer Research Systems and methods for treating patients having a genetic predisposition to develop prostate cancer
US20180282383A1 (en) * 2015-10-02 2018-10-04 University Of Copenhagen Small molecules blocking histone reader domains
EP3420079A4 (fr) * 2016-02-22 2019-07-10 New York Institute of Technology Procédé pour traiter un cancer par désactivation de l'interaction braca1/fancm
CN115998885B (zh) * 2021-10-22 2024-11-12 上海科技大学 抑制剂组合及其在制备治疗myc高表达癌症的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012524A1 (fr) * 2003-07-25 2005-02-10 The University Of Sheffield Utilisation d'arni inhibiteur de l'activite parp pour la fabrication d'un medicament pour le traitement du cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012524A1 (fr) * 2003-07-25 2005-02-10 The University Of Sheffield Utilisation d'arni inhibiteur de l'activite parp pour la fabrication d'un medicament pour le traitement du cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARTZ STEVEN R ET AL: "SMALL INTERFERING RNA SCREENS REVEAL ENHANCED CISPLATIN CYTOTOXICITY IN TUMOR CELLS HAVING BOTH BRCA NETWORK AND TP53 DISRUPTIONS", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 26, no. 24, 1 December 2006 (2006-12-01), pages 9377 - 9386, XP009077057, ISSN: 0270-7306 *
HELLEDAY T ET AL: "DNA repair pathways as targets for cancer therapy", NATURE REVIEWS CANCER 200803 GB, vol. 8, no. 3, March 2008 (2008-03-01), pages 193 - 204, XP002497229, ISSN: 1474-175X 1474-1768 *
MUKHOPADHYAY UTPAL K ET AL: "RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells", CANCER RESEARCH,, vol. 65, no. 7, 1 April 2005 (2005-04-01), pages 2872 - 2881, XP002493344 *
NOGUCHI ET AL: "Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygelda namycin", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 351, no. 3, 11 November 2006 (2006-11-11), pages 658 - 663, XP005726085, ISSN: 0006-291X *
SASAKI R ET AL: "The transcriptional inhibition of DNA repair protein Rad51 enhances radiosensitivity in prostate cancer cells", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 51, no. 3 Supplement 1, 2001, & 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY; SAN FRANCISCO, CA, USA; NOVEMBER 04-08, 2001, pages 56 - 57, XP002497228, ISSN: 0360-3016 *
SCHULTZ N ET AL: "POLY(ADP-RIBOSE) POLYMERASE (PARP-1) JAS A CONTROLLING ROLE IN HOMOLOGOUS RECOMBINATION", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 31, no. 17, 1 September 2003 (2003-09-01), pages 4959 - 4964, XP009045897, ISSN: 0305-1048 *
VENKITARAMAN A R: "Cancer susceptibility and the functions of BRCA1 and BRCA2", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 108, no. 2, 25 January 2002 (2002-01-25), pages 171 - 182, XP002269104, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
GB0707556D0 (en) 2007-05-30
WO2008129239A2 (fr) 2008-10-30

Similar Documents

Publication Publication Date Title
WO2010151755A3 (fr) Traitement de maladies inflammatoires à l'aide du microarn mir-124
WO2012009678A8 (fr) Compositions thérapeutiquement actives et méthode d'utilisation correspondante
WO2007100895A3 (fr) Traitement anticancéreux utilisant des inhibiteurs de gamma-sécrétases
MX357540B (es) Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
WO2011127070A3 (fr) Inhibiteurs d'ire-1α
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
WO2008030538A3 (fr) Thérapie anticancéreuse ciblant les cellules souches cancéreuses
IL196745A (en) Idabanon for use in providing mucosal pathways to treat disease
EP2582682A4 (fr) Procédés pour traiter une affection pulmonaire
MX360640B (es) Diagnosis e imagenologia de cancer.
WO2009114703A3 (fr) Thérapie combinée pour le traitement d'un cancer
HK1214552A1 (zh) 在腎損傷的受試者中用泊馬度胺治療癌症
EP2049899A4 (fr) Méthodes de prévention et de traitement de maladies
WO2008147483A8 (fr) Composés neurogéniques
WO2009103959A3 (fr) Médicament
WO2006138330A3 (fr) Methodes de traitement tissulaire
NZ595440A (en) Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
MY158929A (en) Pharmaceutical combination
WO2008129239A3 (fr) Traitement pour le cancer
WO2008073466A3 (fr) Alpha b-cristalline en tant que traitement de l'inflammation
WO2011031890A3 (fr) Thérapie ciblée sur des cellules souches cancéreuses et contre un cancer pharmacorésistant
WO2011011706A3 (fr) Méthodes et compositions pour le traitement ou la prévention de maladies auto-immunes utilisant des agents immunomodulateurs
CA2866819C (fr) Procede de traitement de l'inflammation
WO2009155070A3 (fr) Compositions et procédés pour le traitement d’inflammation et de lésions hyperkératotiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08736966

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08736966

Country of ref document: EP

Kind code of ref document: A2